Reply by Richardson, Bruce C.
LETTERS 1349 
Reply 
To the Editor: 
Pouchot et a1 describe an interesting case of Cogan’s 
syndrome that improves following therapy with prednisone 
and methotrexate. Many features of this case, including the 
prolonged treatment course, the absence of vasculitis, and 
the steroid-sparing effect of methotrexate, resemble my 
earlier report. However, their patient appears to have re- 
sponded to methotrexate more slowly than my patient, since 
2 years and 3 months elapsed between the institution of the 
methotrexate treatment and the successful tapering of the 
prednisone, whereas in my report, a substantial improve- 
ment was noted after only 3 months of methotrexate treat- 
ment. It is possible that some variability exists in patient 
response to methotrexate. 
The Pouchot et al case highlights the chronic course 
that Cogan’s syndrome can follow. Others have reported 
that Cogan’s syndrome can be extremely variable, lasting 
from several months to more than 15 years (1). Although 
some patients will respond to relatively short courses of 
prednisone (2), prolonged treatment is sometimes necessary. 
In these patients, steroid side effects are likely to become 
problematic. This report and my previous case report both 
suggest that treatment with methotrexate may be helpful in 
this setting. 
As noted by Pouchot et al, Cogan’s syndrome can be 
complicated by systemic vasculitis in 15-21% of patients 
(3,4). The vasculitis often occurs late, 3 weeks to 8 years 
after the onset of disease, with a mean of 7 months (4). Since 
the efficacy of methotrexate in Cogan’s syndroms-associated 
vasculitis is unknown, we agree that all patients should be 
monitored expectantly. More aggressive therapy with drugs 
such as cyclosporine (5) may be indicated should vasculitis 
occur. 
Finally, in both cases, arguments against natural 
disease fluctuations were presented. However, spontaneous 
disease remissions remain possible. I agree with Pouchot et 
a1 that additional experiences should be reported before 
widely recommending methotrexate. Further reports regard- 
ing the use of methotrexate or other steroid-sparing agents in 
Cogan’s syndrome, or other forms of autoimmune hearing 
loss, would be welcome. 
Bruce Richardson, MD, PhD 
University of Michigan, and 
Ann Arbor, MI 
Ann Arbor Veterans Administration Hospital 
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Possible role of bone marrow fat in the development 
of an inflammatory response to sickled erythrocytes: 
comment on the article by Mann and Schumacher 
To the Editor: 
We read with interest the report by Mann and 
Schumacher of inflammation associated with phagocytosis 
of sickled erythrocytes after a fracture into the knee joint 
(Mann D, Schumacher HR Jr: Pseudoseptic inflammatory 
knee effusion caused by phagocytosis of sickled erythro- 
cytes after fracture into the knee joint. Arthritis Rheum 
38:284-287, 1995). In 1961, shortly after demonstration of 
the phlogistic effects of monosodium urate, we aspirated 10 
ml of blood from a man with sickle cell anemia, and 
incubated it under anaerobic conditions for 2 hours, until 
smears showed that all cells were sickled. With the patient’s 
permission, we injected the blood into one of his knee joints. 
There were absolutely no signs or symptoms of an inflam- 
matory response within the next 24 hours. Conversely, we 
have noted intense inflammation after rupture of necrotic fat 
into a contiguous joint space (McCarty DJ, McCarthy G, 
Carrera G: Intraarticular corticosteroids possibly leading to 
local osteonecrosis and marrow fat induced synovitis. J 
Rheumatol 18:1091-1094, 1991). 
Since the patient described by Mann and Schuma- 
cher had a fracture into the joint space, could the phagocy- 
tosed sickled erythrocytes have been opsonized with lyso- 
lecithin or other materials derived from the bone marrow? 
Were the erythrocyte cell membranes preserved around the 
crystalline hemoglobin? It may be premature to assign 
causality to the sickled erythrocytes until Koch’s postulates 
have been fulfilled. 
Daniel J. McCarty, MD 
Medical College of Wisconsin 
Milwaukee, WI 
Roland W. Moskowitz, MD 
Case Western Reserve University 
Cleveland, OH 
Reply 
To the Editor: 
Ms Mann and I thank Drs. McCarty and Moskowitz 
for their comments. We are pleased that our article elicited 
their recollection of their interesting unpublished case study. 
Their failure to demonstrate any inflammation after injecting 
sickled erythrocytes into a joint is surprising, since even 
normal blood does cause inflammation in human hemophilia 
and in animal experiments (1,2). We showed that the cells of 
normal blood were more phlogistic than the plasma. The 
failure to demonstrate inflammation might be related to dose, 
absence of opsonizing material as suggested, or reliance only 
on clinical examination. Considerable inflammation can be 
seen in synovium (3), and at least modest inflammation in 
synovial fluid (4), without clinical signs. 
It would have been interesting to know if the sickled 
cells could have been demonstrated in the joint after 24 
hours, and whether there was anything like the extensive 
phagocytosis of sickled cells that we saw in our patient. Had 
the patient studied by Drs. McCarty and Moskowitz had 
attacks of acute inflammatory arthritis, as our patient had? 
In response to the specific questions, most of our 
patient’s sickled red cells did have intact cell membranes, 
and we saw no obvious adherent material. As is known with 
